Navigation Links
Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
Date:11/16/2013

k of experiencing cardiovascular events.  ISIS-APO(a)Rx is part of Isis' strategy to create a cardiovascular disease franchise comprised of drugs that target all the key components of cardiovascular disease, including various atherogenic lipids, inflammation and thrombosis.

ABOUT Lp(a)
Lp(a) is considered an independent risk factor for cardiovascular disease due to its association with an increased risk of coronary heart disease and atherosclerotic plaque formation.  Lp(a) is a lipoprotein particle that is assembled in the liver that consists of an LDL-C-like particle and apolipoprotein(a).  Lp(a) levels in blood can vary greatly between individuals due primarily to genetic variations in the gene that encodes for apolipoprotein(a).  As a result, Lp(a) levels are genetically determined and remain constant throughout the life of the individual.  Diet and lifestyle changes have little impact on Lp(a) levels and current therapies are not able to adequately reduce elevated levels of Lp(a) to acceptable levels in patients who have severely elevated Lp(a).  As a general guideline for ideal Lp(a) levels, the European Atherosclerosis Society recommends that Lp(a) levels be less than or equal to 50 mg/dL. 

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
2. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
3. ANI Pharmaceuticals To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
4. Ampio Pharmaceuticals to Present at Upcoming Investor Conference
5. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
6. Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results
7. Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
8. Actinium Pharmaceuticals Appoints Richard Steinhart As New Independent Director
9. Inovio Pharmaceuticals Reports 2013 Third Quarter Financial Results
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Third Quarter Financial Results
11. GW Pharmaceuticals to Report 2013 Q4 and Full Year Financial Results and Host Conference Call on 19 November, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... PLEASANTON, Calif., Oct. 28 Thoratec Corporation (Nasdaq: ... circulatory support therapies to save, support and restore failing ... quarter of 2010 increased 40 percent versus the third ... for both the third quarter and first nine months ...
... (NYSE: RMD ) today announced record revenue and ... the quarter ended September 30, 2010 was $282.0 million, a ... over the quarter ended September 30, 2009.  For the quarter ... and net income was $56.7 million, an increase of 26% ...
Cached Medicine Technology:Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 2ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 3ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 4ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 5ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 6
(Date:9/21/2014)... to understand why cancer cells metastasize? Think of Sparta. ... that better prepared them for the demands of battle ... the same thing according to a new study revealing ... grow at the original tumor site, and those that ... cell,s unyielding ability to metastasize is the primary cause ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... designs, develops, implements and supports electronic medical records ... significantly benefited from federal healthcare legislation during the ... to do so during the five years to ... and Clinical Health Act established Medicare and Medicaid ...
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 ... ) have been added over the past month ... that allege serious cardiovascular injuries caused by the ... Case List updated on September 15th shows 2,089 ... the U.S. District Court, District of Massachusetts. These ...
(Date:9/21/2014)... Developers and plugin specialist of ... new transition plugin entitled Transpack Vol. 3 from Pixel ... transitions that will add a level of professionalism to ... Pixel Film Studios. “Blurring the line between professional and ... , Transpack Vol. 3 returns with over 85 all ...
Breaking Medicine News(10 mins):Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2
... , WEDNESDAY, Aug. 24 (HealthDay News) -- ... afford needed health care or prescription drugs, and about ... debt, a new report reveals. Sixty percent of ... 15 million working-age adults lost their jobs between 2008 ...
... , WEDNESDAY, Aug. 24 (HealthDay News) -- High doses ... abnormal heart rhythms and should no longer be prescribed ... Wednesday. Doses of Celexa (citalopram hydrobromide) greater than ... electrical activity of the heart, which can lead to ...
... Nearly three-quarters (72%) of people who lost their health insurance ... said that they skipped needed health care or did ... new Commonwealth Fund report. The same proportion is also struggling ... (49%) who lost jobs but not their health insurance. ...
... diseases (NCDs) such as cancer, diabetes, cardiovascular disease, chronic respiratory ... recent efforts by some countries to stall and weaken critical ... the Liver (EASL) warned today. In a letter ... Jose Manuel Barroso, EASL called on them to personally ...
... -- A rare -- for the East Coast -- earthquake ... Tuesday afternoon, jumbling nerves as far south as Atlanta and ... centered near Louisa, Va., about 85 miles southwest of Washington, ... on the National Mall in Washington, D.C., as well as ...
... the first evidence that older brains get more benefit ... via trial-and-error learning. The study was led ... Toronto and appears online Aug. 24, 2011 in the ... print edition. The finding will surprise professional ...
Cached Medicine News:Health News:Three-Quarters of U.S. Jobless Can't Afford Health Care: Report 2Health News:Three-quarters of those who have lost jobs and health insurance are skipping needed health care 2Health News:Three-quarters of those who have lost jobs and health insurance are skipping needed health care 3Health News:Three-quarters of those who have lost jobs and health insurance are skipping needed health care 4Health News:UN Member States jeopardize international progress on non-communicable disease epidemic 2Health News:5.8-Magnitude Quake Unnerves East Coast 2Health News:Learning information the hard way may be best 'boot camp' for older brains 2
... AquaFlow™ Collagen Glaucoma Drainage Device when ... procedure has been proven to significantly ... the complications often associated with penetrating ... medications. As a result, patient outcomes ...
... Control is a device ... a filter between the ... tubing that captures nuclear ... and efficiency of phaco ...
... is an innovative, stat analyzer that measures ... on-board co-oximetry and integrated data management "all ... include pH, PCO 2 , PO 2 ... sodium, potassium, chloride, ionized calcium, ionized magnesium, ...
... Bio-logic has demonstrated continuous innovations in computerized ... first Digital EEG system brings the latest ... VISION is the first Windows XP Pro ... all your EEG needs: epilepsy monitoring, routine ...
Medicine Products: